The Pandemrix also effective for the elderly

GlaxoSmithKline (GSK) announced Tuesday that a clinical study had demonstrated that its vaccine against influenza A (H1N1), the Pandemrix, was also effective with the first dose in people over 60 years, which had already been reported  for adults and young children.

The new test, conducted in Belgium with 240 people aged 18 to 85 years, showed that the vaccine triggered an immune response well above the levels required by international health authorities, "including the group of older than 60 years", said the British pharmaceutical company, in a statement.

These results add to previous tests that had demonstrated the effectiveness of the vaccine with the first dose in adults and young children, said the group.

"These new data demonstrate the ability of the vaccine to trigger an immune response after one dose, across a wide age group, including seniors," summed up the boss of GSK Biologicals, the division of laboratory dedicated to vaccines.

As noted GSK European authorities currently recommend vaccination against influenza A (H1N1) or "swine flu" as two injections, with at least three weeks of break after each one.

GSK also said that deliveries of vaccine continue, and the number of people who received Pandemrix through vaccination campaigns launched this month in Europe has already reached half a million.

• Usage of Zithromax: A Powerful Antibiotic
• One bed - one habbit
• Be Beneficial by First Aid Training and Courses
• The Advantages of Electric Cigarette Refill
• Researchers managed prevent the aging process in mice
• GPS shoes for Alzheimer patients
• The "standing offices"
• A blood test to know the sex of your child